


RANKED THERAPY OPTIONS

 ON LABEL

 OFF LABEL

 CLINICAL TRIAL

Therapy

- | | |
|---|--|
| A | <p>Cetuximab or panitumumab (+/- Irinotecan or FOLFIRI) - e.g., NCT04117945 or NCT03992456 or NCT04474470
 KRAS wild type, NRAS wild type; EGFR-targeting agents are standard in KRAS/NRAS wild type colorectal cancer; The patient has had prior irinotecan ((10 miles) Duke University Medical Center - Durham, NC - Ireka Burrus, ireka.burrus@duke.edu, 919-668-1861)</p> |
| B | <p>FOLFOX, or CAPEOX +/- bevacizumab - e.g., NCT03597581
 No implicated markers; These are standard combinations for colorectal cancer; The patient has had planned FOLFIRI, had neoadjuvant FOLFIRINOX and FOLFOX + bevacizumab ((10 miles) University of North Carolina Chapel Hill - Chapel Hill, NC - Autumn McRee, MD, 919-843-6286)</p> |
| C | <p>TAS-102 (trifluridine/tipiracil) - e.g., NCT03368963
 No implicated markers; TAS-102 has activity in 5FU-refractory tumors [1]; The patient has not had this class of agents ((332 miles) Emory University Hospital Midtown - Atlanta, GA - Autumn Lunceford, patricia.autumn.lee.lunceford@emory.edu, 404-686-1638)</p> |
| D | <p>A CHK1 inhibitor on a clinical trial - e.g., NCT02632448
 FBXW7 mutation, p53 mutation; This class of agents has limited clinical evidence; The patient has not had this class of agents ((494 miles) Karmanos Cancer Institute - Detroit, MI - Jas Grewal-Karwa, karwaj@karmanos.org, 313-576-8932)</p> |
| E | <p>Regorafenib - e.g., NCT03657641
 No implicated markers; Regorafenib is a standard agent in this disease; The patient has not had this class of agents ((597 miles) Moffitt Cancer Center - Tampa, FL - Richard D. Kim, MD, Richard.Kim@moffitt.org)</p> |
| F | <p>An immunotherapy doublet containing a PD-1/PD-L1 inhibitor on a clinical trial - e.g., NCT03628677 or NCT02964013
 No clinically validated markers; Checkpoint inhibitor combinations are being explored extensively in clinical trials; The patient has not had this type of immunotherapy ((110 miles) Carolina BioOncology Institute - Huntersville, NC - Ashley McClain, amcclain@carolinabiooncology.org, 980-441-1021)</p> |
| G | <p>An immunometabolic agent with a PD-1/PD-L1 inhibitor on a clinical trial - e.g., NCT03454451 or NCT03493945 or NCT03207867
 No implicated markers; Combining checkpoint inhibitors with immunometabolic agents that target IDO1/CD73/CD47/A2AR is a promising strategy; The patient has not had this type of immunotherapy ((108 miles) Carolina BioOncology Institute - Huntsville, NC - Study Coordinator, info@carolinabiooncology.org, 704-947-6599)</p> |
| H | <p>A Wnt inhibitor on a clinical trial - e.g., NCT02521844 or NCT02675946 or NCT03355066
 APC mutation, FBXW7 mutation; This class of agents has limited clinical evidence; The patient has not had this class of agents ((10 miles) Duke University Medical Center, Duke Cancer Center, 20 Duke Medicine Circle - Durham, NC - Joanne Leicester, joanne.leicester@duke.edu, 919-668-1861)</p> |